SCHEMBL2477041

SCHEMBL2477041

Nc1cccc(-c2nn3c(c2-c2ccncc2)SCCC3)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 2/20 0.39
MAPK14 Q16539 2/20 0.37
CYP17A1 P05093 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP19A1 P11511 2/20 0.36
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
PIK3CA P42336 2/20 0.35
ALOX5 P09917 1/20 0.34
MEN1 O00255 1/20 0.34
PSIP1 O75475 1/20 0.34
AXL P30530 1/20 0.34
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
KDM4E B2RXH2 1/20 0.33
CSNK1D P48730 1/20 0.32
CSNK1E P49674 1/20 0.32
FYN P06241 1/20 0.32
NTRK1 P04629 1/20 0.32
TGFBR1 P36897 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2478554 0.93 CYP17A1 (0.37) MPOMAPK14CYP17A1CYP3A4CYP19A1
SCHEMBL2478416 0.86 FYN (0.40) MPOMAPK14CYP17A1CYP3A4CYP19A1
SCHEMBL2480248 0.86 MPO (0.39) MPOMAPK14TGFBR1
SCHEMBL3465911 0.84 FYN (0.45) MPOMAPK14CYP11B2PIK3CACSNK1D
SCHEMBL2481707 0.83 RAB9A (0.36) MPOMAPK14TGFBR1
SCHEMBL2476673 0.81 BCHE (0.44) CYP3A4ALOX5MEN1
SCHEMBL2481441 0.79 RAB9A (0.39) MPOMAPK14CYP19A1TGFBR1
SCHEMBL2479421 0.79 FYN (0.41) MPOMAPK14CYP17A1CYP3A4CYP19A1
SCHEMBL2474825 0.76 SMN1; SMN2 (0.49) KDR
SCHEMBL2480457 0.76 TAAR1 (0.43) CYP3A4MEN1CSNK1DCSNK1ENTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US claimed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP claimed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO claimed
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K19, MAP4K3, MAP3K15 MPO 4542/4885MAPK14 60/4885CYP17A1 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.